Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study

International Journal of Retina and Vitreous

  ^{1    1    1    1    1    1    2    3} 

[1] 0000 0000 8934 4045, grid.67033.31, New England Eye Center, Tufts Medical Center, Box 450, 800 Washington Street, 02111, Boston, MA, USA;0000 0000 8934 4045, grid.67033.31, New England Eye Center, Tufts Medical Center, Box 450, 800 Washington Street, 02111, Boston, MA, USA;0000 0001 0514 7202, grid.411249.b, School of Medicine, Federal University of São Paulo, São Paulo, Brazil;0000 0000 8934 4045, grid.67033.31, New England Eye Center, Tufts Medical Center, Box 450, 800 Washington Street, 02111, Boston, MA, USA;Hospital de Olhos do Parana, Curitiba, Brazil;

关键词: Central serous chorioretinopathy;    Eplerenone;    Mineralocorticoid inhibitors;   

DOI  :  10.1186/s40942-019-0190-y

来源: publisher

【 摘 要 】

BackgroundIncreased mineralocorticoid activity is one of the plausible causes of chronic central serous chorioretinopathy (CSCR) and mineralocorticoid inhibitors such as eplerenone have been investigated as its potential therapy. This study investigates the short-term safety and efficacy of oral eplerenone in patients with chronic CSCR.Patients and methodsProspective study of 13 eyes of 13 patients with the diagnosis of chronic CSCR. All patients received eplerenone 50 mg/day for 4 weeks. Enhanced depth imaging optical coherence tomography (OCT) was obtained. Best corrected visual acuity (BCVA), and OCT parameters including sub retinal fluid (SRF), choroidal thickness (CT) and central macular thickness (CMT), were measured manually.ResultsThe mean SRF height decreased slightly at 1-month follow-up as compared to baseline, but the change was not statistically significant (94.18 ± 17.53 vs. 113.15 ± 18.69; p = 0.08). Subfoveal CT and CMT was significantly reduced as compared to baseline (6.6% [p = 0.002] and 7.05% [p = 0.04], respectively). The BCVA did not change significantly (20/28 vs. 20/30 [p = 0.16]).ConclusionThis study suggests that oral eplerenone may be used as a safe and potentially effective treatment in chronic CSCR, however there are minimal short-term effects on subretinal fluid or visual acuity therefore therapeutic trials longer than one month are necessary to test its benefits.Trial registration Clinicaltrials.gov identification number: NCT01822561. Registered 3/25/13, https://clinicaltrials.gov/ct2/show/study/NCT01822561

【 授权许可】

CC BY